Speech dysfluency exacerbated by levodopa in Parkinson's disease

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 562-565

  Louis, Elan D ^a,b   Winfield, Linda ^b   Fahn, Stanley ^b   Ford, Blair ^b  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUORODEOXYGLUCOSE; LEVODOPA; NEUROTRANSMITTER; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE;

ADULT; AGED; ARTICLE; CASE REPORT; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFUSION; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SPEECH DISORDER;

EID: 0035353758     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1081     Document Type: Article

References (36)

1. Rosenberger PB. Dopaminergic systems and speech fluency. J Fluency Disord 1980;5:255-267.
2. Brady JP. The pharmacology of stuttering: a critical review. Am J Psychiatry 1991;148:1309-1316.
3. Prins D, Mandelkorn T, Cerf FA. Principal and differential effects of haloperidol and placebo treatments upon speech dysfluencies in stutterers. J Speech Lang Hear Res 1980;23:614-629.
4. Lapointe LL, Horner J. Palilalia: a descriptive study of pathological reiterative utterences. J Speech Hear Disord 1981;46:34-38.
5. Bloodstein O. The development of stuttering. II. Developmental phases. J Speech Hear Disord 1960;25:366-376.
6. Andrews G, Harris M. The syndrome of stuttering. London: Spastics Society Medical Education and Information Unit in Association with Wm. Heinemann Medical Books; 1964.
7. Wingate ME. Stuttering: Theory and treatment. New York: Irvington; 1976.
8. Van Riper C. The nature of stuttering. 2nd Ed. Englewood Cliffs, NJ: Prentice Hall; 1982.
9. Craig A. An investigation into the relationship between anxiety and stuttering. J Speech Hear Disord 1990;55:290-294.
10. Tolosa ES, Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984;34:1516-1518.
11. Ludlow CL, Rosenberg J, Salazar A, Grafman J, Smutok M. Site of penetrating brain lesions causing chronic acquired stuttering. Ann Neurol 1987;22:60-66.
12. Soroker N, Bar-Israel Y, Schechter I, Solzi P. Stuttering as a manifestations of right-hemispheric subcortical stroke. Eur Neurol 1990;30:268-270.
13. Carluer L, Marié R-M, Lambert, et al. Acquired and persistent stuttering as a main symptom of striatal infarction. Mov Disord 2000;15:343-346.
14. Nass R, Schreter B, Heier L. Acquired stuttering after a second stroke in a two-year- old. Dev Med Child Neurol 1994;36:70-83.
15. Aron ML. The effects of the combination of trifluoperazine and amylobarbitone on adult stutterers. S Afr J Med Sci 1965;11:227-237.
16. Wells PG. Haloperidol in the treatment of stutter. Med J Aust 1974;3:613.
17. Swift WJ, Swift EW, Arelleno M. Haloperidol as a treatment for adult stuttering. Compr Psychiatry 1975;16:61-67.
18. Murray TJ, Kelly P, Rosenberg E. The treatment of stuttering with haloperidol. Can J Neurol Sci 1977;4:219.
19. Fahn S. The freezing phenomenon in Parkinsonism. Adv Neurol 1995;67:53-63.
20. Narabayashi H, Kondo T, Yokochi F, Nagatsu T. Clinical effects of L-threo-3,4- dihydroxyphenylserine in cases of parkinsonism and pure akinesia. Adv Neurol 1986;45:593-602.
21. Imai H, Narabayashi H, Sakata E. "Pure akinesia" and later added supranuclear ophthalmoplegia. Adv Neurol 1986;45:207-212.
22. Anderson JM, Hughes JD, Rothi LJ, Crucian GP, Heilman KM. Developmental stuttering and Parkinson's disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry 1999;66:776-778.
23. Hier DB, Hagenlocker K, Shindler AG. Language disintegration in dementia: effects on etiology and severity. Brain Lang 1985;25: 117-133.
24. Kent RD, Lapointe LL. Acoustic properties of pathologic reiterative utterances: a case study of palilalia. J Speech Hear Res 1982; 25:95-99.
25. Fahn S. Hypokinesia and hyperkinesia. In: Goetz CG, Pappert EJ, eds. Textbook of clinical neurology. New York: W.B. Saunders Company; 1999.
26. Critchley EM. Speech disorder of Parkinsonism: a review. J Neurol Neurosurg Psychiatry 1981;44:751-758.
27. Boller F, Albert M, Denes F. Palilalia. Br J Disord Com 1975;10: 92-97.
28. Foti DJ, Cummings JL. Neurobehavioral aspects of movement disorders. In: Watts RL, Koller WC, eds. Movement disorders: neurological principles and practice. New York: McGraw Hill; 1997.
29. Haerer AF, ed. DeJong's the neurological examination. 5th Ed. Philadelphia: Lippincott-Raven; 1992.
30. Ackermann H, Grone BF, Hoch G, Schonle PW. Speech freezing in Parkinson's disease: a kinematic analysis of orofacial movements by means of electromagnetic articulography. Folia Phoniatrica 1993;45:84-89.
31. Claveria LE, Calne DB, Allen JG. "On-off" phenomena related to high plasma levodopa. Br Med J 1973;2:641-647.
32. Marsden CD, Parkes JD. "On-off" effects with Parkinson's disease on chronic levodopa therapy. Lancet 1976;292-296.
33. Critchley EMR. Peak dose dysphonia in Parkinsonism. Lancet 1976;7958:544.
34. Supprian T, Retz W, Deckert J. Clozapine-induced stuttering: epileptic brain activity? Am J Psychiatry 1999;156:1663-1664.
35. Ebeling TA, Compton AD, Albright DW. Clozapine-induced stuttering. Am J Psychiatry 1997;154:1473.
36. Thomas P, Lalaux N, Vaiva G, Goudemand M. Dose-dependent stuttering and dystonia in a patient taking clozapine. Am J Psychiatry 1994;1512:1096.